Premium
Hesperidin Supplementation Alleviates Oxidative DNA Damage and Lipid Peroxidation in Type 2 Diabetes: A Randomized Double‐Blind Placebo‐Controlled Clinical Trial
Author(s) -
Homayouni Fatemeh,
Haidari Fatemeh,
Hedayati Mehdi,
Zakerkish Mehrnoosh,
Ahmadi Kambiz
Publication year - 2017
Publication title -
phytotherapy research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.019
H-Index - 129
eISSN - 1099-1573
pISSN - 0951-418X
DOI - 10.1002/ptr.5881
Subject(s) - hesperidin , malondialdehyde , lipid peroxidation , placebo , glycemic , medicine , type 2 diabetes , diabetes mellitus , oxidative stress , antioxidant , gastroenterology , pharmacology , endocrinology , chemistry , biochemistry , pathology , alternative medicine
This study aimed to examine the effects of hesperidin supplement on the glycemic parameters, oxidative DNA damage, and lipid peroxidation in patients with type 2 diabetes. Sixty‐four patients were randomly allocated to receive 500 mg/day hesperidin or placebo capsules for 6 weeks. Data on glycemic parameters, total antioxidant capacity (TAC), 8‐hydroxydeoxyguanosine (8‐OHDG), and malondialdehyde (MDA) were collected at the baseline and at the end of the study. In hesperidin group, TAC increased (0.74 ± 0.16 vs. 0.82 ± 0.18), while serum froctoseamin (5.79 ± 5.86 vs. 5.01 ± 4.95; p = 0.001), 8‐OHDG (14.32 ± 6.4 vs. 11.00 ± 7.0; p = 0.000), and MDA (5.78 ± 1.76 vs. 4.60 ± 0.75; p = 0.000) decreased in comparison with the baseline values. There was a significant difference in percent change of TAC (13.35 ± 19.21 vs. 3.13 ± 10.02; p = 0.043), froctoseamin (−10.10 ± 16.84 vs. 4.27 ± 34.646), 8‐OHDG (−25.11 ± 28.23 vs. 8.69 ± 35.41; p = 0.000), and MDA (−16.46 ± 18.04 vs. −1.82 ± 22.63; p = 0.007) between hesperidin and control groups following intervention in adjusted models. These results suggest that hesperidin may improve TAC and alleviate serum froctoseamin, 8‐OHDG, and MDA levels in type 2 diabetes. Copyright © 2017 John Wiley & Sons, Ltd.